Navigation Links
Genetic Differences Predict Anti-Inflammatory Benefits From Nutritional Products
Date:9/25/2007

acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual report on Form 10-K for the year ended December 31, 2006 as amended, filed with the Securities and Exchange Commission, our quarterly reports on Form 10- Q and other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.

For Interleukin Genetics:

Paul Voegelin (781) 398-0700

Additional Contacts for Media / Investors:

Erin Duggan (212) 445-8238, Weber Shandwick

Rich Tauberman (201) 964-2408, Financial Relations Board


'/>"/>
SOURCE Interleukin Genetics
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
4. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
5. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
6. Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting
7. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
8. Researchers Identify New Genetic Risk Factors for Type 2 Diabetes
9. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
10. Myriad Genetics Presents Tumor Origin Technology at AACR
11. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/8/2008)...ept. 8 /- Novo Nordisk (NYS...data from a phase 3 clinical study,(LEAD(TM) 4) to...ociation,for the Study of Diabetes that demonstrat..., a human GLP-1 analog, to metformin and rosiglita... improved blood glucose lowering,(HbA1c), weight l...
(Date:9/5/2008)...TON, Fla., Sept. 5 /PRNewswire-USNewswire/ -- The ... recently awarded Florida,Atlantic University rese...sor and director of the Center for Molecular Biolo...lege of Science, and CHS,Resources LLC (CHS), $184...ercialization Assistance Grant program (SURECAG). ...
(Date:9/5/2008)... Demonstrates microRNAs Extracted From a Simple Bl...Clinical Biomarkers for a Wide Range of ...ary Technology, Rosetta Genomics is Currently Deve...Colon Cancer, REHOVOT, Israel and JERSEY CITY, Ne...setta Genomics, Ltd. (NASDQ: ROSG), a leader in,th...
(Date:9/4/2008)...a Published in ,The Lancet, and Presented at ESC C...esults from a new international,study, the GISSI H...ose of,omega-3 acid ethyl esters reduced all cause...lar reasons in patients with chronic heart,failure...ne version of ,The,Lancet, and were presented at t...
Breaking Medicine Technology:Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes 2Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes 3Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes 4Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes 5Major State Grant Accelerates Research and Development of Novel Cancer Therapy 2Major State Grant Accelerates Research and Development of Novel Cancer Therapy 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 2Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 4New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4Lettuces Roots Lure Salmonella 3474 1Lettuces Roots Lure Salmonella 3474 2Lettuces Roots Lure Salmonella 3474 3Anticlotting drug found to be safe in sickle cell patients 3472 1Anticlotting drug found to be safe in sickle cell patients 3472 2MIT links gene to cholesterol 761 1MIT links gene to cholesterol 761 2Select Medical Corporation to Announce Third Quarter Results on Monday November 12 3470 1
...abetes Patients -, MONTREAL, March 26 /CNW/ - Co...ounced positive preliminary results from its,Pha...ment of Type 2,diabetes using the Company,s prop...tudy demonstrated that PC-DAC(TM):Exendin-4 was,...ce-weekly at each,of the dosing levels tested, l...
... from ECLIPSE, Largest Safety,Program of Intraveno... 2007 /PRNewswire-FirstCall/ -- Favorable,findings...ipine),compared to current intravenous antihyperte...sion -- a potentially harmful,elevation in blood p...- were presented for the first time at a late-brea...
Other Medicine Technology:PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 2PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 3PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results,Demonstrate Safety and Efficacy at Once-Weekly Dosing 4Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 2Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 3Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 4Pivotal Phase III Findings With Investigational Drug Cleviprex,(Clevidipine) Demonstrate Perioperative Blood Pressure Control In,Cardiac Surgery 5
(Date:9/8/2008)...aser scalpels, arthroscopic,surgery, genomic resea...rinary medicine is quickly expanding into new high...e benefit; it,s improving medicine for,people, too... care for their pets to,treat diseases like diabet... according to the American Veterinary Medical Asso...
(Date:9/8/2008)...zine examines Iraq and Afghanistan veterans, strug..., Washington, DC (PRWEB) S...by veterans of the Iraq and Afghanistan wars about... addiction disorders are featured in the current i...ublication of the National Council for Community B...
(Date:9/7/2008)...f older patients successfully treated for colorect...le to detect any recurrence of cancer. The study, ... , a peer-reviewed journal of the American Cancer ...monitoring of colorectal cancer survivors could af...y curative surgery for colorectal cancer have an i...
(Date:9/7/2008)... appear to lower a man,s PSA level, the blood biom...her a man is at risk of prostate cancer. , But t.... 8 in the journal Cancer , caution that men shou... prostate cancer just yet. , "We showed that me...rin and other non-steroidal anti-inflammatory drug...
Breaking Medicine News(10 mins):Health News:High-Tech Vet Medicine Saving Lives of Pets and People 2Health News:Helping Veterans in Our Communities 2Health News:Helping Veterans in Our Communities 3Health News:Many colorectal cancer survivors do not receive recommended follow-up care 2Health News:Common painkillers lower levels of prostate cancer biomarker 2
...ore functions in reproduction than merely being a ...ts that the semen from fertile men contains a mult...cle Stimulating Hormone) initiates ovulation. Some... role in the maintenance of pregnancy. The researc...
...boast of their first FDA-approved pill capable of ...y due to the creation// of a new molecule by a res...tified by the name TMC-114, and also known by the ...molecules that are still under creation by Arun Gh...
...guards and NHS red tape following the Alder Hey bo...dicines, according to researchers//. With restrict...perwork, and seemingly arbitrary judgments by ethi...eterred from getting studies up and running. Jenn...
...e health implication when tiny particles in the ai...er scientists demonstrated that when rats inhale//...ay and make it to many regions in the brain. This ...mental Health Perspectives. There were also eviden...
Other Medicine News:Health News:Finally, The First Ever Treatment for Drug-Resistant HIV 2Health News:Finally, The First Ever Treatment for Drug-Resistant HIV 3Health News:Finally, The First Ever Treatment for Drug-Resistant HIV 4Health News:Medical researchers being stifled by NHS Red tape 2Health News:Nano-sized inhaled particles traverse quickly from nose to brain 2
Accurately tests for Nystagmus when rotated at 8-10 rpm. Drums are 10" high by 8" diameter. Light weight drum of professional quality with ball bearings for effortless spin mechanism. For use 24 to 3
Sterile squares of textured nylon foil for repair of the floor of the orbit.
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile
Segment stand magnifiers come complete with bar magnifier to achieve a higher magnification while still maintaining a wide binocular field of view.
Medicine Products: